P. Fortomaris

A pathogenic myxoma virus in vaccinated and non-vaccinated commercial rabbits

A case of a myxoma virus strain in vaccinated and non-vaccinated rabbits is described, and genetic identification of that strain was performed in this study. In two commercial farms being 150km apart, myxomatosis has been occurred after the import of animals from a common supplier. The disease was manifested firstly in the existing non-immune population of does and fatteners, and later in all vaccinated animals, being 2-3 months immune at the time of first symptoms. Morbidity was almost 100% with nasal discharge, listlessness, fever, eyelid swelling, eye and nasal purulent discharge, papules in the ears, facial oedema, and swelling of the anagenital region, with result always the death of the animals. Examination by PCR had shown the presence of a 492-bp specific product in all the symptomatic animals tested from both farms, having 100% nucleotide sequence identity with the homologous region of the myxoma virus Lausanne strain. The simultaneous occurrence of myxomatosis in the vaccinated and non-vaccinated rabbits of both farms, suggests that the supplier was possibly the source of a viral isolate with increased virulence.

Effect of lameness on milk production in a flock of dairy sheep.

LAMENESS in sheep has been the subject of scientific investigations because of its effects on production and animal welfare. Lameness is a clinical sign, not a disease in itself, and the causes can be broadly classified as genetic, physical injury and infection ([Coulon and others 1996][1], [Warnick

Dietary supplementation of encapsulated organic acids enhances performance and modulates immune regulation and morphology of jejunal mucosa in piglets

The aim of the study was to test two encapsulated regimens containing organic acids and/or zinc oxide (ZnO) on weaned piglet performance and jejunal mucosa morphology and immunity. For that, weaned piglets were allocated to treatments including control, supplemented with encapsulated organic acids (ACID group), and supplemented with organic acids and ZnO, both encapsulated (ACIDplus group). Antibiotics were used at similar concentrations in all groups during the first two weeks, but withdrawn from the ACIDplus group during the last three weeks of the experiment. ZnO was given with feed in the Control and ACID groups only during the first two weeks. The experimental period lasted 5 weeks. Piglets from the ACID group exhibited higher average daily gain compared to other groups during the last 3 weeks of the experiment (P<0.05). The ACIDplus group performed similarly with controls. The mucosal height of jejunum was higher in both ACID (P<0.01) and ACIDplus groups compared to controls (P<0.05). Immunohistochemical analysis of jejunal mucosa, showed higher numbers of neutrophils in ACID and ACIDplus groups compared to controls (P<0.01 and P<0.001, respectively). Treatments had the opposite effect on mucosal regulatory T-cells (Foxp3-positive cells) in jejunum, being higher (P<0.001) in control group compared to ACID and ACIDplus groups. The number of CD3-positive cells was higher (P<0.05) in the ACIDplus and control groups compared to the ACID group. In conclusion, the encapsulated products used had beneficial effects on growth performance coexisting with improvements on jejunal histomorphology and modulation of mucosal immunity.